Association of matrix metalloproteinases (MMP2, MMP7 and MMP9) genetic variants with left ventricular dysfunction in coronary artery disease patients

Clinica Chimica Acta

Volumn 413, Issue 19-20, 2012, Pages 1668-1674

  Mishra, Avshesh ^a   Srivastava, Anshika ^a   Mittal, T ^a   Garg, N ^a   Mittal, B ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Coronary artery disease; LVD; LVEF; MMPs genetic variants

Indexed keywords

GELATINASE A; GELATINASE B; MATRILYSIN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MATRIX METALLOPROTEINASE 2 GENE; MATRIX METALLOPROTEINASE 7 GENE; MATRIX METALLOPROTEINASE 9 GENE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REPLICATION STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; VALIDATION STUDY;

AGED; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HEART VENTRICLES; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MODELS, MOLECULAR; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84864395027     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.05.012     Document Type: Article

References (43)

1. Roncalli J., Tongers J., Losordo D.W. Update on gene therapy for myocardial ischaemia and left ventricular systolic dysfunction or heart failure. Arch Cardiovasc Dis 2010, 103:469-476.
2. Srivastava A., Garg N., Mittal T., et al. Association of 25 bp deletion in MYBPC3 gene with left ventricle dysfunction in coronary artery disease patients. PLoS One 2011, 6:e24123.
3. Mishra A., Srivastava A., Mittal T., Garg N., Mittal B. Impact of renin-angiotensin-aldosterone system gene polymorphisms on left ventricular dysfunction in coronary artery disease patients. Dis Markers 2011, 31:1-9.
4. Gunja-Smith Z., Morales A.R., Romanelli R., Woessner J.F. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. Am J Pathol 1996, 148:1639-1648.
5. Spinale F.G., Coker M.L., Thomas C.V., Walker J.D., Mukherjee R., Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 1998, 82:482-495.
6. Peterson J.T., Li H., Dillon L., Bryant J.W. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res 2000, 46:307-315.
7. Spinale F.G., Coker M.L., Heung L.J., et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000, 102:1944-1949.
8. Lindsey M.L., Gannon J., Aikawa M., et al. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 2002, 105:753-758.
9. Rohde L.E., Ducharme A., Arroyo L.H., et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999, 99:3063-3070.
10. Creemers E.E., Cleutjens J.P., Smits J.F., Daemen M.J. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?. Circ Res 2001, 89:201-210.
11. Spinale F.G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002, 90:520-530.
12. Brown D.L., Hibbs M.S., Kearney M., Loushin C., Isner J.M. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995, 91:2125-2131.
13. Noji Y., Kajinami K., Kawashiri M.A., et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 2001, 39:380-384.
14. ""Yasmin, McEniery C.M., Wallace S., et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005, 25:372.
15. Tayebjee M.H., Lip G.Y., Tan K.T., Patel J.V., Hughes E.A., MacFadyen R.J. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol 2005, 96:339-345.
16. Hu X.F., Jin X.P., Hu P.Y., et al. Association of a functional polymorphism in the MMP7 gene promoter with susceptibility to vulnerable carotid plaque in a Han Chinese population. Clin Chem Lab Med 2011, 49:1735-1741.
17. Alp E., Menevse S., Tulmac M., Yilmaz A., Yalcin R., Cengel A. The role of matrix metalloproteinase-2 promoter polymorphisms in coronary artery disease and myocardial infarction. Genet Test Mol Biomarkers 2010, 15:193-202.
18. Zhi H., Wang H., Ren L., et al. Functional polymorphisms of matrix metallopeptidase-9 and risk of coronary artery disease in a Chinese population. Mol Biol Rep 2011, 37:13-20.
19. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986, 57:450-458.
20. Devlin B., Roeder K. Genomic control for association studies. Biometrics 1999, 55:997-1004.
21. Rickham P.P. Human experimentation. Code of Ethics of the World Medical Association. Declaration of Helsinki. BMJ 1964, 2:177.
22. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989, 2:358-367.
23. Johnson R., McNutt P., MacMahon S., Robson R. Use of the Friedewald formula to estimate LDL-cholesterol in patients with chronic renal failure on dialysis. Clin Chem 1997, 43:2183-2184.
24. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
25. Singh R., Srivastava P., Srivastava A., Mittal R.D. Matrix metalloproteinase (MMP-9 and MMP-2) gene polymorphisms influence allograft survival in renal transplant recipients. Nephrol Dial Transplant 2010, 25:3393-3401.
26. Malik M.A., Sharma K.L., Zargar S.A., Mittal B. Association of matrix metalloproteinase-7 (-181A>G) polymorphism with risk of esophageal squamous cell carcinoma in Kashmir Valley. Saudi J Gastroenterol 2011, 17:301-306.
27. Pollanen P.J., Lehtimaki T., Mikkelsson J., et al. Matrix metalloproteinase3 and 9 gene promoter polymorphisms: joint action of two loci as a risk factor for coronary artery complicated plaques. Atherosclerosis 2005, 180:73-78.
28. Wang L., Ma Y.T., Xie X., et al. Association of MMP9 gene -1562 C/T polymorphism with myocardial infarction in Uighur population of Xinjiang. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2011, 28:180-184.
29. Horne B.D., Camp N.J., Carlquist J.F., et al. Multiple-polymorphism associations of 7 matrix metalloproteinase and tissue inhibitor metalloproteinase genes with myocardial infarction and angiographic coronary artery disease. Am Heart J 2007, 154:751-758.
30. Wu N., Lu X., Hua Y., et al. Haplotype analysis of the stromelysin-1 (MMP3) and gelatinase B (MMP9) genes in relation to coronary heart disease. Ann Hum Genet 2009, 73:404-410.
31. Blankenberg S., Rupprecht H.J., Poirier O., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003, 107:1579-1585.
32. Morgan A.R., Zhang B., Tapper W., Collins A., Ye S. Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J Mol Med 2003, 81:321-326.
33. Nanni S., Melandri G., Hanemaaijer R., et al. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms. Transl Res 2007, 149:137-144.
34. Wang L., Ma Y., Xie X, et al. Association of MMP-9 gene polymorphisms with acute coronary syndrome in the Uygur population of China. World J Emerg Med 2011, 2:104-110.
35. Wu S., Hsu L.A., Teng M.S., et al. Association of matrix metalloproteinase 9 genotypes and cardiovascular disease risk factors with serum matrix metalloproteinase 9 concentrationsin Taiwanese individuals. Clin Chem Lab Med 2010, 48:543-549.
36. Wagner D.R., Delagardelle C., Ernens I., Rouy D., Vaillant M., Beissel J. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail 2006, 12:66-72.
37. Kelly D., Khan S.Q., Thompson M., et al. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J 2008, 29:2116-2124.
38. Kelly D., Cockerill G., Ng L.L., et al. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 2007, 28:711-718.
39. Rodius S., Mulliert G., Azuaje F., Devaux Y., Wagner D.R. Matrix metalloproteinase 9 polymorphism and outcome after myocardial infarction. Cardiogenetics 2011, 1.
40. Murphy G., Knauper V. Relating matrix metalloproteinase structure to function: why the "hemopexin" domain?. Matrix Biol 1997, 15:511-518.
41. Aureli L., Gioia M., Cerbara I., et al. Structural bases for substrate and inhibitor recognition by matrix metalloproteinases. Curr Med Chem 2008, 15:2192-2222.
42. O'Farrell T.J., Pourmotabbed T. Identification of structural elements important for matrix metalloproteinase type V collagenolytic activity as revealed by chimeric enzymes. Role of fibronectin-like domain and active site of gelatinase B. J Biol Chem 2000, 275:27964-27972.
43. Zhang B., Ye S., Herrmann S.M., et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999, 99:1788-1794.